2023-503729-20-00CompletedPhase 1
Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Jul 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 15 Sept 2023
- Start date
- 27 Mar 2024
- Lead sponsor
- Othair Prothena Limited
- Diseases
- Alzheimer disease
- EU CT number
- 2023-503729-20-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 40
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari General de Catalunya | Barcelona | Spain | Completed |
| Fundació ACE, Institut Català de Neurociències Aplicades | Barcelona | Spain | Completed |
| PROMENTE Sp. z o.o. | Bydgoszcz | Poland | Completed |
| Centrum Medyczne Neuromed Sp. z.o.o. | Bydgoszcz | Poland | Completed |
| Neurologia Śląska Centrum Medyczne | Katowice | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.